» Articles » PMID: 30652552

Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology

Abstract

Purpose: To develop a public-private partnership to study the feasibility of a new approach in collecting and analyzing clinically annotated imaging data from landmark phase III trials in advanced solid tumors.

Patients And Methods: The collection of clinical trials fulfilled the following inclusion criteria: completed randomized trials of > 300 patients, highly measurable solid tumors (non-small-cell lung cancer, colorectal cancer, renal cell cancer, and melanoma), and required sponsor and institutional review board sign-offs. The new approach in analyzing computed tomography scans was to transfer to an academic image analysis laboratory, draw contours semi-automatically by using in-house-developed algorithms integrated into the open source imaging platform Weasis, and perform serial volumetric measurement.

Results: The median duration of contracting with five sponsors was 12 months. Ten trials in 7,085 patients that covered 12 treatment regimens across 20 trial arms were collected. To date, four trials in 3,954 patients were analyzed. Source imaging data were transferred to the academic core from 97% of trial patients (n = 3,837). Tumor imaging measurements were extracted from 82% of transferred computed tomography scans (n = 3,162). Causes of extraction failure were nonmeasurable disease (n = 392), single imaging time point (n = 224), and secondary captured images (n = 59). Overall, clinically annotated imaging data were extracted in 79% of patients (n = 3,055), and the primary trial end point analysis in each trial remained representative of each original trial end point.

Conclusion: The sharing and analysis of source imaging data from large randomized trials is feasible and offer a rich and reusable, but largely untapped, resource for future research on novel trial-level response and progression imaging metrics.

Citing Articles

Comparing quantitative imaging biomarker alliance volumetric CT classifications with RECIST response categories.

Zhao B, Obuchowski N, Yang H, Chou Y, Ma H, Guo P Radiol Adv. 2025; 2(1):umaf001.

PMID: 39834611 PMC: 11739520. DOI: 10.1093/radadv/umaf001.


Modeling Tumor Growth Using Partly Conditional Survival Models: A Case Study in Colorectal Cancer.

Flynn J, Curry M, Zhao B, Yang H, Dercle L, Tito Fojo A JCO Clin Cancer Inform. 2023; 7:e2200203.

PMID: 37713655 PMC: 10569775. DOI: 10.1200/CCI.22.00203.


Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trials.

Dercle L, Yang M, Gonen M, Flynn J, Moskowitz C, Connors D Eur Radiol. 2023; 33(12):9254-9261.

PMID: 37368111 DOI: 10.1007/s00330-023-09862-z.


Radiomic and Volumetric Measurements as Clinical Trial Endpoints-A Comprehensive Review.

Funingana I, Piyatissa P, Reinius M, McCague C, Basu B, Sala E Cancers (Basel). 2022; 14(20).

PMID: 36291865 PMC: 9599928. DOI: 10.3390/cancers14205076.


An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans.

Dercle L, Zhao B, Gonen M, Moskowitz C, Connors D, Yang H Eur J Cancer. 2021; 161:138-147.

PMID: 34916122 PMC: 10018811. DOI: 10.1016/j.ejca.2021.10.029.


References
1.
Chiou V, Burotto M . Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol. 2015; 33(31):3541-3. PMC: 4622096. DOI: 10.1200/JCO.2015.61.6870. View

2.
Tan Y, Schwartz L, Zhao B . Segmentation of lung lesions on CT scans using watershed, active contours, and Markov random field. Med Phys. 2013; 40(4):043502. PMC: 3618093. DOI: 10.1118/1.4793409. View

3.
Douillard J, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M . Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014; 25(7):1346-1355. DOI: 10.1093/annonc/mdu141. View

4.
Oxnard G, Zhao B, Sima C, Ginsberg M, James L, Lefkowitz R . Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol. 2011; 29(23):3114-9. PMC: 3157977. DOI: 10.1200/JCO.2010.33.7071. View

5.
Peeters M, Douillard J, Van Cutsem E, Siena S, Zhang K, Williams R . Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol. 2012; 31(6):759-65. DOI: 10.1200/JCO.2012.45.1492. View